Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority trial of indacaterol + glycopyrronium inhalation powder versus 杰润® in stable COPD
CTR20264039Phase 3Active
- Sponsor
- Guangzhou Respiratory Drug Engineering Technology
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Guangzhou Respiratory Drug Engineering Technology. Primary endpoint: Change from baseline in trough FEV1 after 12 weeks of treatment. Started Oct 2026; status: active.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20264039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264039.